Results 101 to 110 of about 10,900 (261)

Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK

Journal of Medical Economics, 2020
Aims Respiratory syncytial virus (RSV) is a common cause of respiratory infection in infants and severe infection can result in hospitalization. The passive immunization, palivizumab, is used as prophylaxis against RSV, however, use in the UK is ...
O. Narayan, A. Bentley, K. Mowbray, M. Hermansson, Dominic Pivonka, E. Kemadjou, J. Belsey   +6 more
semanticscholar   +1 more source

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro

The Turkish Journal of Pediatrics
Background. Respiratory syncytial virus (RSV) is one of the most common pathogens causing severe lower respiratory tract disease in infancy and childhood.
Envera Lekic, Ljubinka Dragas, Drasko Nikcevic, Jasmina Lekic, Ana Dedic, Ljiljana Sulovic   +5 more
doaj   +1 more source

Respiratory Syncytial Virus Infection in Patients with Hematological Diseases: Single-Center Study and Review of the Literature [PDF]

, 2017
Background.Respiratory syncytial virus (RSV) causes significant mortality in patients with hematological diseases, but diagnosis and treatment are uncertain.
Decker, Michael, Fluckiger, Ursula, Gratwohl, Alois, Halter, Jörg, Heim, Dominik, Hirsch, Hans H., Khanna, Nina, Steffen, Ingrid, Weisser, Maja, Widmer, Andreas F.   +9 more
core  

Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites [PDF]

, 2012
The vast majority of anti-infective therapeutics on the market or in development are small molecules; however, there is now a nascent pipeline of biological agents in development.
Bishop-Hurley, Sharon L., Cooper, Matthew A., Huang, Johnny X.   +2 more
core   +1 more source

Management of Infants Treated for Respiratory Viral Infections: A Finnish Retrospective Register‐Based Study

Health Science Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background and Aims Viral respiratory tract infections are common in all age groups, and they are responsible for a vast number of health care visits every year. Furthermore, the incidence of respiratory infections is the highest in children.
Sallamaria Länsisalo, Paula Heikkilä, Sauli Palmu   +2 more
wiley   +1 more source

Human and bovine respiratory syncytial virus vaccine research and development [PDF]

, 2008
Human (HRSV) and bovine (BRSV) respiratory syncytial viruses (RSV) are two closely related viruses, which are the most important causative agents of respiratory tract infections of young children and calves, respectively.
Deplanche, Martine, Meyer, Gilles, Schelcher, François   +2 more
core   +2 more sources

Respiratory Syncytial Virus (RSV) in an Italian Pediatric Cohort: Genomic Analysis and Circulation Pattern in the Season 2022–2023

Journal of Medical Virology, Volume 97, Issue 11, November 2025.
ABSTRACT There is growing interest in the molecular surveillance of the respiratory syncytial virus (RSV) and data concerning the virus molecular epidemiology in high‐risk pediatric patients in Italy are still limited. A total of 127 RSV‐positive swabs collected in 2022–2023 season were analyzed.
Alessia Lai, Annalisa Bergna, Valentina Fabiano, Carla della Ventura, Hanin Chmes, Alice Romero, Martina Loiodice, Angela Maria Dolores Boria, Alessandro Campagnoli, Felicia Stefania Falvella, Alberto Dolci, Gian Vincenzo Zuccotti, Gianguglielmo Zehender   +12 more
wiley   +1 more source

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar

International Journal of General Medicine, 2018
Ahmad Abushahin, Ibrahim Janahi, Amjad Tuffaha Department of Pediatrics, Section of Pediatric Pulmonology, Hamad Medical Corporation, Doha, Qatar Objective: The primary objective of this study was to document the hospitalization rate due to ...
Abushahin A, Janahi I, Tuffaha A
doaj  

Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein [PDF]

, 2014
Infections with human respiratory syncytial virus (HRSV) occur globally in all age groups and can have devastating consequences in young infants. We demonstrate that a vaccine based on the extracellular domain (SHe) of the small hydrophobic (SH) protein ...
Bert Schepens, Brian Gilbert, Cherrie AH, Connors M, Glezen WP, Kenny Roose, Koen Sedeyn, Liesbeth Vande Ginste, Lieselot Houspie, Marc Van Ranst, Michael Schotsaert, Mills JT, Nicholas JA, Nico Rooijen, Olmsted RA, Pedro Piedra, Sarah De Baets, Ventre K, Walter Fiers, Whitehead SS, Xavier Saelens   +20 more
core   +3 more sources

Real‐World Effectiveness of Nirsevimab in Preventing RSV Hospitalizations: Evidence of Protection in Southern Italian Infants, 2024–2025

Journal of Medical Virology, Volume 97, Issue 11, November 2025.
ABSTRACT Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants, resulting in millions of cases and hundreds of thousands of deaths worldwide every year. Nirsevimab, a long‐acting monoclonal antibody approved in 2023, has 75%–90% protection against RSV‐related admissions.
Francesca Fortunato, Rosa Prato, Angelo Acquafredda, Angelo Campanozzi, Valeria Delli Carri, Rosa Francavilla, Giuseppina Iannelli, Pio Liberatore, Gianfranco Maffei, Matteo Mariano, Loris Micelli, Marilena Nesta, Maria Rosa Pastore, Annamaria Calvo, Matteo Rinaldi, Pier Luigi Lopalco, Domenico Martinelli   +16 more
wiley   +1 more source